New Data Presented At NANS 2014 Demonstrate Long-Term, Low Back Pain Relief With Boston Scientific Precision Spectra™ Spinal Cord Stimulator System

MARLBOROUGH, Mass., Dec. 12, 2014 /PRNewswire/ -- New retrospective data evaluating the Boston Scientific Corporation (NYSE: BSX) Precision Spectra^™ Spinal Cord Stimulator (SCS) System demonstrate that the device provided sustained, highly significant relief of low back pain 12 months after implantation. Results from the PRO Study are being presented this weekend at the 18th North American Neuromodulation Society (NANS) meeting in Las Vegas.

The outcomes review of 213 patients at 13 centers focuses on patients with chronic pain and chronic low back pain who are receiving treatment with the Precision Spectra SCS System. The system's Illumina™ 3D Software, an anatomy-driven computer model designed for simple point-and-click pain targeting, helps to address a key challenge in long term back pain relief: stimulating the neural target without stimulating undesired areas.

At 12 months post-implantation, results include:

• Sustained and significant reduction in overall pain measured on the 0-10 numeric rating scale (NRS) was reported, from an average baseline score of 7.17, to an average score of 2.96 at 12 months post-implantation (N= 178).
• In patients with only low back pain (N= 73), a sustained and significant reduction of low back pain (measured on the 0-10 NRS scale) was reported, from an average baseline score of 7.21 to an average of 3.17 at 12 months post-implantation.
• In patients with severe low back pain (N= 41, baseline score of 8 or greater measured on the 0-10 NRS scale), sustained and significant reduction in pain was reported, from an average score of 8.60 at baseline to 2.87 at 12 months post-implantation.

This cohort will be followed through the 24-month interval.

"Treating low back pain has been challenging because so many therapies have had mixed results," said Salim Hayek, M.D., Ph.D., chief, Division of Pain Medicine at University Hospitals of Cleveland and lead study investigator. "These results demonstrate that the Precision Spectra System can provide effective, long-term relief for patients suffering from this difficult to treat condition."

"When designing the next-generation Precision Spectra SCS System, we included new, innovative technologies with the goal of treating low back pain more effectively," said Maulik Nanavaty, president, Neuromodulation, Boston Scientific. "This long-term, 'real-world' study reflects our continuing commitment to advancing the science of pain relief to help achieve better outcomes for patients with chronic pain."

Together with the clinical data presented at NANS, additional presentations will describe an advanced research program of investigational studies of Boston Scientific SCS systems. These studies include ACCELERATE, a prospective multicenter trial evaluating conventional high-rate (10 kHz) spinal cord stimulation in the management of chronic, intractable pain, and WHISPER, a prospective multicenter trial evaluating the use of sub-perception multiple independent current control (MICC) SCS at up to 1.2 kHz.

About Chronic Pain

More than 100 million Americans suffer from chronic pain. Living in constant pain for an extended period of time can have a devastating impact on quality of life for many patients; without relief, or the hope for relief, many patients lose the ability to sleep, work and function normally. In particular, conventional spinal cord stimulator therapy can be effective in treating low back pain but not all patients get optimal relief. As a result, there is a continuing need for new therapies and technologies to meet this very specific pain area.

About the Precision Spectra SCS System

Recently, Popular Mechanics magazine awarded the Precision Spectra System the 2014 "Breakthrough Award" in the field of medical devices for its innovation in meeting the needs of patients with chronic pain.The Precision Spectra SCS System is the world's first and only SCS system with Illumina 3D™ software and 32 contacts, which is designed to provide improved pain relief to a wide range of patients who suffer from chronic pain. Prior to the release of the Precision Spectra SCS System, SCS systems offered a maximum of 16 contacts and two lead ports, with each lead port allowing the placement of a single lead. Additional lead ports give physicians more flexibility to cover their patients' pain at the time of implant and more flexibility to adapt to changing pain patterns in the future. With more contacts, the Precision Spectra SCS System also offers more coverage of the spinal cord for the management of chronic pain.

The upgradeable Precision Spectra SCS System is designed to improve pain relief using the innovative and highly advanced Illumina 3D Software, a three dimensional anatomy-driven computer model. A key challenge in SCS therapy is stimulating the neural target without stimulating undesired areas. By taking into account the conductivity of 3D anatomical structures and physician placement of the SCS leads, the Illumina 3D Software is designed for simple point-and-click pain targeting. To view or download an image of the Precision Spectra SCS System, click here.

About Boston Scientific

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding our products, our business plans, presentations, clinical trials and impact of data, product performance and impact, and competitive offerings.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT:   
Media: Ryan Davenport
Global Media Relations
Boston Scientific Corporation
763-494-2664 (office)
[email protected]

Investors: Susie Lisa, CFA
Investor Relations
Boston Scientific Corporation
508-683-5565 (office)
[email protected]

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-data-presented-at-nans-2014-demonstrate-long-term-low-back-pain-relief-with-boston-scientific-precision-spectra-spinal-cord-stimulator-system-300008946.html

SOURCE Boston Scientific

Related Links

http://www.bostonscientific.com